Cystic Fibrosis Treatment Accessibility
While medical advancements in the Cystic Fibrosis Market have significantly improved patient life expectancy, global accessibility remains a concern. In low- and middle-income countries, the cost of CFTR modulators is prohibitive, and diagnostic capabilities are often limited. This disparity results in delayed diagnoses and poorer outcomes.
Nonprofit organizations, patient advocacy groups, and pharmaceutical companies are working together to improve affordability through tiered pricing models, expanded patient-assistance programs, and partnerships with public healthcare systems. Bridging this accessibility gap is essential for equitable healthcare outcomes.
2 Views